TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by BNP Paribas Financial Markets

BNP Paribas Financial Markets trimmed its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 49.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 59,710 shares of the biopharmaceutical company’s stock after selling 58,275 shares during the quarter. BNP Paribas Financial Markets’ holdings in TG Therapeutics were worth $1,797,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of TGTX. Clearbridge Investments LLC purchased a new position in TG Therapeutics in the 4th quarter worth approximately $55,237,000. Raymond James Financial Inc. purchased a new position in TG Therapeutics in the 4th quarter worth approximately $14,508,000. Braun Stacey Associates Inc. purchased a new position in TG Therapeutics in the 4th quarter worth approximately $13,328,000. Norges Bank purchased a new position in TG Therapeutics in the 4th quarter worth approximately $12,085,000. Finally, Penn Capital Management Company LLC purchased a new position in TG Therapeutics in the 4th quarter worth approximately $10,577,000. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Stock Up 2.3%

TGTX stock opened at $34.36 on Friday. The firm has a market cap of $5.45 billion, a PE ratio of -343.57 and a beta of 2.21. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The firm’s 50 day moving average price is $38.59 and its 200-day moving average price is $33.96. TG Therapeutics, Inc. has a one year low of $15.16 and a one year high of $46.48.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.16). The firm had revenue of $120.86 million for the quarter, compared to analysts’ expectations of $117.07 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm’s quarterly revenue was up 90.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.07) EPS. On average, equities research analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on TGTX. StockNews.com raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 4th. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price target on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $40.80.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.